Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan.
Arashiro T, Arima Y, Kuramochi J, Muraoka H, Sato A, Chubachi K, Yanai A, Arioka H, Uehara Y, Ihara G, Kato Y, Yanagisawa N, Ueda A, Kato H, Oka H, Nishida Y, Nidaira Y, Asami T, Jinta T, Nakamura A, Oba K, Taniyama D, Yamamoto K, Tanaka K, Ueshima K, Fuwa T, Stucky A, Suzuki T, Smith C, Hibberd M, Ariyoshi K, Suzuki M. Arashiro T, et al. Among authors: fuwa t. Open Forum Infect Dis. 2023 May 3;10(6):ofad240. doi: 10.1093/ofid/ofad240. eCollection 2023 Jun. Open Forum Infect Dis. 2023. PMID: 37351451 Free PMC article.
Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan.
Arashiro T, Arima Y, Kuramochi J, Muraoka H, Sato A, Chubachi K, Oba K, Yanai A, Arioka H, Uehara Y, Ihara G, Kato Y, Yanagisawa N, Nagura Y, Yanai H, Ueda A, Numata A, Kato H, Oka H, Nishida Y, Ishii K, Ooki T, Nidaira Y, Asami T, Jinta T, Nakamura A, Taniyama D, Yamamoto K, Tanaka K, Ueshima K, Fuwa T, Stucky A, Suzuki T, Smith C, Hibberd M, Ariyoshi K, Suzuki M. Arashiro T, et al. Among authors: fuwa t. Vaccine. 2023 Nov 13;41(47):6969-6979. doi: 10.1016/j.vaccine.2023.10.021. Epub 2023 Oct 13. Vaccine. 2023. PMID: 37839947 Free article.
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
Transferrin Biosynthesized in the Brain Is a Novel Biomarker for Alzheimer's Disease.
Hoshi K, Ito H, Abe E, Fuwa TJ, Kanno M, Murakami Y, Abe M, Murakami T, Yoshihara A, Ugawa Y, Saito T, Saido TC, Matsumoto K, Yamaguchi Y, Furukawa K, Arai H, Kanai M, Miyajima M, Arai H, Ogawa N, Akatsu H, Hashizume Y, Tateno H, Honda T, Hashimoto Y. Hoshi K, et al. Among authors: fuwa tj. Metabolites. 2021 Sep 10;11(9):616. doi: 10.3390/metabo11090616. Metabolites. 2021. PMID: 34564432 Free PMC article.
Rapid increase of 'brain-type' transferrin in cerebrospinal fluid after shunt surgery for idiopathic normal pressure hydrocephalus: a prognosis marker for cognitive recovery.
Murakami Y, Matsumoto Y, Hoshi K, Ito H, Fuwa TJ, Yamaguchi Y, Nakajima M, Miyajima M, Arai H, Nollet K, Kato N, Nishikata R, Kuroda N, Honda T, Sakuma J, Saito K, Hashimoto Y. Murakami Y, et al. Among authors: fuwa tj. J Biochem. 2018 Sep 1;164(3):205-213. doi: 10.1093/jb/mvy043. J Biochem. 2018. PMID: 29701803
108 results